AU2021322092A1 - Classifying tumors and predicting responsiveness - Google Patents

Classifying tumors and predicting responsiveness Download PDF

Info

Publication number
AU2021322092A1
AU2021322092A1 AU2021322092A AU2021322092A AU2021322092A1 AU 2021322092 A1 AU2021322092 A1 AU 2021322092A1 AU 2021322092 A AU2021322092 A AU 2021322092A AU 2021322092 A AU2021322092 A AU 2021322092A AU 2021322092 A1 AU2021322092 A1 AU 2021322092A1
Authority
AU
Australia
Prior art keywords
therapy
group
gene
markers
immunomodulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021322092A
Other languages
English (en)
Inventor
David HOUT
Tyler Jon NIELSEN
Brian Z. Ring
Douglas T. Ross
Brock Lloyd SCHWEITZER
Robert Scott SEITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Molecular Diagnostics Inc
Original Assignee
Insight Molecular Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Molecular Diagnostics Inc filed Critical Insight Molecular Diagnostics Inc
Publication of AU2021322092A1 publication Critical patent/AU2021322092A1/en
Assigned to Insight Molecular Diagnostics, Inc. reassignment Insight Molecular Diagnostics, Inc. Amend patent request/document other than specification (104) Assignors: ONCOCYTE CORPORATION
Assigned to INSIGHT MOLECULAR DIAGNOSTICS INC. reassignment INSIGHT MOLECULAR DIAGNOSTICS INC. Amend patent request/document other than specification (104) Assignors: Insight Molecular Diagnostics, Inc.
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
AU2021322092A 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness Pending AU2021322092A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060321P 2020-08-03 2020-08-03
US63/060,321 2020-08-03
US202063121837P 2020-12-04 2020-12-04
US63/121,837 2020-12-04
US202163173180P 2021-04-09 2021-04-09
US63/173,180 2021-04-09
PCT/US2021/044240 WO2022031630A1 (en) 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness

Publications (1)

Publication Number Publication Date
AU2021322092A1 true AU2021322092A1 (en) 2023-03-02

Family

ID=80118483

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021322092A Pending AU2021322092A1 (en) 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness

Country Status (8)

Country Link
US (1) US20230296584A1 (enExample)
EP (1) EP4188330A4 (enExample)
JP (1) JP2023536636A (enExample)
KR (1) KR20230058410A (enExample)
CN (1) CN116322639A (enExample)
AU (1) AU2021322092A1 (enExample)
CA (1) CA3188358A1 (enExample)
WO (1) WO2022031630A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用
CN121737300A (zh) * 2025-12-18 2026-03-27 湖南师范大学 用于无创检测口腔癌的联用肿瘤标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517229B2 (en) * 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
EP2922972B1 (en) * 2012-11-26 2017-04-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
GB201512869D0 (en) * 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2018132916A1 (en) * 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
SG11202005613SA (en) * 2017-12-19 2020-07-29 Abraxis Bioscience Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
US20210396739A1 (en) * 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途

Also Published As

Publication number Publication date
US20230296584A1 (en) 2023-09-21
CN116322639A (zh) 2023-06-23
CA3188358A1 (en) 2022-02-10
KR20230058410A (ko) 2023-05-03
EP4188330A4 (en) 2024-09-04
JP2023536636A (ja) 2023-08-28
WO2022031630A1 (en) 2022-02-10
EP4188330A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
JP7408534B2 (ja) 分子機能プロファイルを生成、視覚化、及び分類するためのシステム及び方法
US12152075B2 (en) Treatment of renal cell carcinoma
CN114556480A (zh) 肿瘤微环境的分类
JP2018505658A (ja) Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
KR20190016025A (ko) 고형 암을 갖는 환자의 분류 방법
WO2014022826A2 (en) Biomarker associated with risk of melanoma reoccurrence
US20230296584A1 (en) Classifying tumors and predicting responsiveness
JP2024511166A (ja) 癌の標的療法
US20230119171A1 (en) Biomarker panels for stratification of response to immune checkpoint blockade in cancer
JP7772700B2 (ja) 神経膠芽腫を処置するための方法
US20240084391A1 (en) Diagnostic Methods and Methods of Treatment of Ovarian Cancer
EP4473313A2 (en) Classifying tumors and predicting responsiveness
WO2019178214A1 (en) Methods and compositions related to methylation and recurrence in gastric cancer patients
HK40095165A (en) Classifying tumors and predicting responsiveness
Jørgensen et al. E‐POSTERS
HK40102168A (en) Diagnostic methods and methods of treatment of ovarian cancer
KR20250176146A (ko) Rna 기반 면역항암제 반응성의 예측 방법
CN117321225A (zh) 癌症的靶向疗法

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: INSIGHT MOLECULAR DIAGNOSTICS, INC.

Free format text: FORMER NAME(S): ONCOCYTE CORPORATION

Owner name: INSIGHT MOLECULAR DIAGNOSTICS INC.

Free format text: FORMER NAME(S): INSIGHT MOLECULAR DIAGNOSTICS, INC.